SALT LAKE CITY, Feb. 21 /PRNewswire/ -- Axial Biotech, a company revolutionizing spine care through the development of molecular diagnostic and motion preserving technologies, announced today that it has named Eric K. Olson as the company's new Executive Vice President of Sales and Marketing. Axial Biotech intends to launch their first product, a DNA-based pre-symptomatic and prognostic test to determine the risk for developing severe scoliosis, later this year.
"On behalf of the Axial Biotech Directors, I am excited to welcome Mr. Olson, a leader of the highest caliber with an extensive and proven track record in the medical device industry," said Chairman Kenneth Ward, M.D. "Olson's experience in management, global sales, and marketing, and his success in achieving profitable growth in domestic and international medical markets, make him uniquely qualified among the many candidates we considered for this position," Dr. Ward stated.
Olson comes equipped with 18 years of successful experience in sales and marketing within the medical device industry. He has led top-producing sales and marketing teams in organizations ranging from pre-IPO start-ups to Fortune 500 companies.
Prior to his Axial Biotech experience, he was Vice President of Sales and Marketing for Facet Solutions, Inc. Facet Solutions designed and developed the Anatomic Facet Replacement System (AFRS(TM)), the first anatomic facet reconstruction device designed to provide patients with lumbar spinal stenosis, a motion preservation alternative to fusion.
Olson obtained a bachelor's degree in Behavioral Science and Health Administration with a minor in Japanese from the University of Utah, together with a master's-level internship from the same university.
"As we approach the commercialization of the first genetic prognostic test for idiopathic scoliosis later this year, I am pleased that we have secured such a talented and experienced sales and marketing professional as Eric Olson" stated John M. Climaco, President and CEO. "He brings with him the depth and breadth of spine-market experience that will assist us in translating the benefits of our molecular diagnostic technology to surgeons and patients around the world."
"I am convinced that Axial Biotech is in a position to change the way that clinicians are able to treat Adolescent Idiopathic Scoliosis," said Olson. "I am enthusiastic about the opportunity to help further the company to industry leadership."
About Axial Biotech, Inc.
Axial Biotech, Inc. is a privately held, venture-backed company founded in 2002 by a group of internationally recognized spine surgeons and geneticists. The company is focused on developing and commercializing DNA-based pre-symptomatic and prognostic tests, as well as motion-preserving technologies for common spinal disorders. The company's headquarter and laboratory is located in Salt Lake City, Utah.
CONTACT: John M. Climaco, President and Chief Executive Officer of Axial
Biotech, Inc., +1-801-984-9100, jclimaco@axialbiotech.com
Web site: http://www.axialbiotech.com/
